A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the
safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant
glioma. ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each
patient will participate in only 1 dose group and will receive up to 6 cycles of treatment
provided there is no evidence of tumor progression, there is recovery to ≤Grade 1 or baseline
nonhematologic, ANG1005-related toxicity (except alopecia), the absolute neutrophil count is
≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.